leadf
logo-loader
AIM:DEST

Destiny Pharma PLC

Receive alerts
Market:
AIM
Market Cap:
£27.3 m
Price
62.00 GBX
Change
0.00%
52 weeks high
114.56
52 weeks low
28.99

In brief

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives.

Our lead asset, XF-73, is currently recruiting patients into a Phase 2b clinical trial for the prevention of post-surgical infection.

We are looking to build a portfolio of novel antimicrobial drug products from our XF drug platform that can access markets closed to traditional antibiotics due to the threat of antimicrobial resistance (AMR), generic competition and pricing challenges.